|
US2020352156A1
|
|
Pharmaceutical composition comprising a cyclic peptide of formula x1-gqretpegaeakpwy-x2 and use for extracorporeal lung treatment
|
|
US2020299331A1
|
|
Composition Comprising a Peptide and an Inhibitor of Viral Neuraminidase
|
|
CN108025038A
|
|
Treat the ring type polypeptide of 1B types PHA
|
|
EA034620B1
|
|
Dry-powder peptide medicament
|
|
KR20160127017A
|
|
Attenuation of intrapulmonary inflammation
|
|
CN105188734A
|
|
Lyophilisate containing a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2
|
|
CN105188735A
|
|
Pharmaceutical composition comprising a cyclic peptide of formula x1 -gqretpegaeakpwy-x2 and use for extracorporeal lung treatment
|
|
EP2679239A1
|
|
Pharmaceutical compound for treating the pulmonary form of altitude sickness caused by oxygen deprivation and reduced air pressure
|
|
AT510585B1
|
|
COMPOSITION COMPRISING A PEPTIDE AND AN INHIBITOR OF VIRAL NEURAMINIDASE
|
|
EP2397151A1
|
|
Treatment of vascular complications of diabetes
|
|
AT509267A1
|
|
Organic compounds for the regulation of vector ion channels
|
|
AT507953A1
|
|
Method for avoiding and treating hyperpermeability
|
|
EP2219663A1
|
|
Reverse protein
|
|
NZ585889A
|
|
Cyclic protein free from cysteines
|
